2021-22 Academic Calendar (PDF)
« All Events
Alina Baum is an Associate Director in Infectious Diseases at Regeneron Pharmaceuticals, where she is leading the COVID-19 spike antibody program. She received her PhD in molecular virology from the lab of Adolfo Garcia-Sastre at Mount Sinai School of Medicine and performed postdoctoral studies with Charlie Rice at Rockefeller University. Her academic career focused on studying interactions between RNA viruses and the innate immune system. In her current position at Regeneron, Dr. Baum is leading a virology research group developing novel therapies for viral infections, including emerging pathogens such as Ebola and SARS-CoV-2, as well as developing oncolytic viruses and therapeutic vaccines for cancer immunotherapy.
Meagan O’Brien is a Senior Director of Early Clinical Development and Clinical Experimental Sciences at Regeneron Pharmaceuticals. Dr. O’Brien received her medical degree from Harvard Medical School and completed medical residency and a fellowship in infectious diseases in New York City at Columbia Presbyterian and New York University Medical Schools. Dr. O’Brien’s NIH-sponsored basic science, translational, and clinical academic research focused on innate immune dysregulation by chronic viral infections and chronic inflammation in HIV infection. Dr. O’Brien joined Regeneron in 2017 to work in Early Clinical development, with a focus on allergy and immunology, infectious diseases, and rare disease.
Register here to receive Zoom log-in information.